Johnson & Johnson announced positive Phase 2b COPERNICUS study results showing low rates of rash, blood clots, and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in treating advanced non-small cell lung cancer with EGFR mutations. The study involved 214 diverse patients and demonstrated fewer than 1% treatment discontinuations due to related adverse events at one year, improving on previous intravenous treatment data. These findings support RYBREVANT FASPRO plus LAZCLUZE as a first-line treatment option with a better patient experience through less frequent dosing and prophylactic care. The study reflects Johnson & Johnson's commitment to advancing cancer treatment delivery and management in real-world settings.
Johnson & Johnson (JNJ) shares are trading at USD 266.32 as of September 15, 2026, 09:51 WIB, just below their 52-week high of USD 278.43, showing resilience in the health sector. The stock's 1-day gain of 0.28% contrasts with its 52-week low of USD 174.16, highlighting strong market confidence possibly supported by positive clinical trial news like the COPERNICUS study. With a market cap of $640.02 billion and a dividend yield of 2.02%, JNJ remains a significant player in healthcare innovation and investment.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even ...
Johnson & Johnson reported a 96% drop in GAAP net earnings for Q3 due to a one-time legal charge related to talc litigation, but adjusted earnings fell only 7.5%. The company raised its full-year adjusted EPS guidance and maintained a strong dividend...
